

November 12, 2007

NIHON KOHDEN CORPORATION (6849)

Stock Exchange Listing: 1st section Tokyo Stock Exchange Head Office: Tokyo

Representative: Kazuo Ogino, President and CEO

Takeshi Akahane, Corporate Director, General Manager, Managing and Planning Dept. Contact: Phone: +81 / 3-5996-8003 (URL http://www.nihonkohden.com/)

1. Consolidated Financial Highlights for the 1st Half of FY2007 (From April 1, 2007 to September 30, 2007)

(1) Consolidated Operating Results (Amounts are rounded down to the nearest million ven)

(1) Consolidated Operating Results								on yon,			
	Net sales		Net sales		Operating prof	Operating profit		Ordinary profit		Net income	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%			
First half FY2007	50,730	7.7	4,863	47.5	4,918	38.2	2,938	43.4			
First half FY2006	47,113	15.6	3,296	32.5	3,558	27.9	2,049	-5.7			
FY2006	96,679		7,973	•	8,448	•	5,052				

	Net income	Net income
	per share- Basic	per share - Diluted
	yen	yen
First half FY2007	66.72	_
First half FY2006	46.23	_
FY2006	114.12	_

(Note) Investment income for equity method:

First half FY2007: - 4 million yen First half FY2006: 18 million yen FY2006: 46 million yen

(2) Consolidated Financial Conditions

	Total assets	Net assets	Equity ratio	Net assets per share
	Millions of yen Millions of ye		%	Yen
First half FY2007	73,310	51,010	69.1	1,150.04
First half FY2006	72,274	47,211	64.9	1,057.93
FY2006	75,894	48,864	63.9	1,101.41

(Note) Equity:

First half FY2007: 50,644 million yen First half FY2006: 46,892 million yen FY2006: 48,503 million yen

(3) Consolidated Cash Flows

(5) Consolidated Cash Flows	•			
	Cash flows from	Cash flows from Cash flows from		Cash and cash equivalents, end
	operating activities	investing activities	financing activities	of the period
	Millions of yen	Millions of yen	Millions of yen	Millions of yen
First half FY2007	5,021	-1,073	-1,567	13,403
First half FY2006	2,693	-1,301	-831	11,404
FY2006	5,882	-3,050	-2,591	11,027

2. Dividends

	Dividends per share				
	Interim Year end		Total		
	yen	yen	yen		
FY2006	15.00	15.00	30.00		
FY2007	17.00		34.00		
FY2007 (Forecast)	_	17.00	34.00		

3. Consolidated Forecast for FY2007 (From April 1, 2007 to March 31, 2008)

The company has revised the forecast for FY2007, previously announced on May 18, 2007.

	Net sales		Operating p	orofit	Ordinary p	orofit	Net inco	me	Net income per share- Basic
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	yen
Full year	102,800	6.3	9,500	19.1	9,600	13.6	6,000	18.7	136.25

(Note) Percentage figures in the above tables indicate increase/decrease over the corresponding period of previous year.



4. Other

(1) Change in Scope of consolidation: None

(2) Changes in Accounting Rules, Procedures, Presentation Method, etc. for the Consolidation Financial Statement: Yes

(3) Number of outstanding shares (Common Stock)

Number of outstanding shares at the end of the period:

First half FY2007: 45,765,490 First half FY2006: 45,765,490 FY2006: 45,765,490

Number of treasury stocks:

First half FY2007: 1,728,640 First half FY2006: 1,441,173 FY2006: 1,727,745

(Reference) Non-Consolidated Financial Highlights

1. Non-Consolidated Financial Highlights for the 1st Half of FY2007 (From April 1, 2007 to September 30, 2007)

(1) Non-Consolidated Operating Results

(Amounts are rounded down to the nearest million yen)

_	(1) 1 (oli Collegiante a Pera	(Timounto are Tounava do Wil to the nearest mini-							1011 5 0115
		Net sales		Operating profit		Ordinary profit		Net income	
Ī		Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
	First half FY2007	33,040	9.5	4,033	48.4	4,542	26.8	3,022	22.9
	First half FY2006	30,165	19.2	2,718	41.9	3,582	26.0	2,458	-14.4
	FY2006	62,231		6,387		7,675		5,310	

	Net income
	per share- Basic
	yen
First half FY2007	68.62
First half FY2006	55.47
FY2006	119.94

(2) Non-Consolidated Financial Conditions

	Total assets	Net assets	Equity ratio	Net assets per share
	Millions of yen	Millions of yen	%	Yen
First half FY2007	66,752	46,717	70.0	1,060.86
First half FY2006	66,758	43,213	64.7	974.94
FY2006	67,734	44,558	65.8	1,011.83

(Note) Equity:

First half FY2007: 46,717 million yen First half FY2006: 43,213 million yen FY2006: 44,558 million yen

2. Non-Consolidated Forecast for FY2007 (From April 1, 2007 to March 31, 2008)

The company has revised the forecast for FY2007, previously announced on May 18, 2007.

	Net sales		Operating p	rofit	Ordinary pr	rofit	Net incom	ne	Net income per share- Basic
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	yen
Full year	67,000	7.7	7,600	19.0	8,400	9.4	5,500	3.6	124.90

(Note) Percentage figures in the above tables indicate increase/decrease over the corresponding period of previous year.

^{*} The above estimates are based on information available on the date of this report's announcement. Actual results may differ from such estimates due to unforeseen circumstances.



5. Review of Operations

During the term under review (April 1, 2007 to September 30, 2007), as the Japanese government made progress on National Health Insurance reform, the business environment remained severe for medical equipment suppliers. Outside Japan, competition intensified as western companies expanded their business scale through M&A as well as the rise of emerging Asian companies. Under these circumstances, to strengthen our organization and business structures, Nihon Kohden has started a new 3-year business plan, SPEED UP II, for the period until FY2009 (ending March 2010).

Japan: Although AED (automated external defibrillators) experienced strong sales growth due to the increased penetration of AEDs in the PAD (public access defibrillation) market, sales in the university market and public hospital market decreased from the first half of prior year when the Company had large-scale orders for information systems. As a result, domestic sales decreased 1.2% over the first half of FY2006, to ¥36,766 million. Patient Monitors sales increased due to higher sales of bedside monitors and clinical information systems. Sales of Treatment Equipment and Medical Supplies also increased steadily. In Physiological Measuring Equipment, sales of ECG and polygraphs decreased due to sluggish sales of system network products, while EEG sales increased.

International: Sales in North America increased due to solid sales of Patient Monitors. Sales of Patient Monitors and Medical Supplies in Latin America soared mainly due to the shipment of the balance of large-scale orders, which was carried forward from the prior year. Sales in Europe were up with good performance in Patient Monitors, hematology analyzers and Medical Supplies. Sales in China were weak mainly due to lower ECG sales, while sales in other Asian countiries increased with higher sales of Patient Monitors. As a result, international sales increased 41.3% over the first half of fiscal 2006, to ¥13,964 million.

Overall sales during the term under review increased 7.7% over the first half of FY2006 to ¥50,730 million. Operating profit, ordinary profit and net profit also increased as a result of higher sales and higher gross profit ratio, primarily due to a favorable product mix with increased sales of our own products. Operating profit increased 47.5% to ¥4,863 million, ordinary profit increased 38.2% to ¥4,918 million and net income increased 43.4% to ¥2,938 million over the first half of prior year.

6. Consolidated Sales Results of First half FY2007 by Product Segment

(Millions of yen)

		First half FY2007	First halt	f FY2006	
	Amount	Amount Growth rate Composition Amount		Amount	Growth rate
	Amount	(%)	(%)	Timount	(%)
Physiological Measuring Equipment	7,356	-10.9	14.5	8,252	23.8
Patient Monitors	11,276	24.4	22.2	9,065	7.3
Treatment Equipment	7,640	12.3	15.1	6,804	25.0
Medical Supplies	16,453	18.4	32.4	13,897	4.1
Other Medical Equipment	8,003	-12.0	15.8	9,094	32.9
Total	50,730	7.7	100.0	47,113	15.6
(Reference) Overseas Sales	13,964	41.3	27.5	9,886	9.6

7. Consolidated Forecast for FY 2007 by Product Segment

	FY2007 (Forecast)				
	Amount	Growth rate	Composition		
	Amount	(%)	(%)		
Physiological Measuring Equipment	16,500	0.1	16.1		
Patient Monitors	22,100	12.3	21.5		
Treatment Equipment	15,300	13.4	14.9		
Medical Supplies	32,100	9.2	31.2		
Other Medical Equipment	16,800	-4.7	16.3		
Total	102,800	6.3	100.0		
(Reference) Overseas Sales	26,100	19.0	25.4		



8. Consolidated Financial Statements

(1) Consolidated Balance Sheets

(1) Consolidated Balance Sheets	Ei al le Exte	1006	Y1 . 1 10 YX	200=	(Millions of yen)		
	First half FY2 Amount	2006 %	First half FY: Amount	2007	FY2006 Amount	%	
A GODDING	Amount	/0	Amount	/0	Amount	/0	
ASSETS							
Current Assets:	11 440		12 412		11.060		
Cash	11,440		13,413		11,060		
Trade notes and accounts receivable	26,326		26,192		28,805		
Inventories	14,829		13,321		15,008		
Deferred income taxes	3,098		2,818		3,214		
Other current assets	915		882		947		
Allowance for doubtful receivables	-154	=0.4	-142	0	-128		
Total current assets	56,455	78.1	56,485	77.0	58,908	77.6	
Fixed Assets:							
Tangible fixed assets:							
Buildings and structures	2,981		3,190		3,189		
Machinery, equipment and vehicles	690		652		697		
Tools, furniture and fixtures	2,357		2,596		2,639		
Land	2,499		2,550		2,499		
Construction in progress	401		238		288		
Total tangible fixed assets	8,930	12.4	9,229	12.6	9,314	12.3	
Intangible fixed assets	804	1.1	1,010	1.4	1,043	1.4	
Investments and other assets:					ĺ		
Investments in securities	4,769		4,616		4,910		
Deferred income taxes	21		4,010		4,910		
Prepaid pension expenses	21		888				
Other investments and other assets	1,660		1,382		2,064		
Allowance for doubtful receivables	-366		-325		-366		
Total investments and other assets	6,084	8.4	6,585	9.0		8.7	
	15,819	21.9	16,825	23.0	16,985	22.4	
Total Assets	72,274	100.0	73,310	100.0	75,894	100.0	
Total Assets	12,214	100.0	73,310	100.0	73,074	100.0	
LIABILITIES							
Current Liabilities:							
Trade notes and accounts payable	15,921		13,318		16,121		
Short-term debt	2,840		1,718		2,522		
Other payables	551		763		859		
Accrued income taxes	1,326		1,611		1,923		
Accrued expenses	1,519		1,675		1,938		
Accrued bonuses	1,464		1,537		1,806		
Accrued bonuses to directors and corporate auditors					77		
Other current liabilities	831		1,147		1,127		
Total current liabilities	24,454	33.8	21,772	29.7	26,376	34.7	
Non-current liabilities:							
Long-term debt	137		40		111		
Long-term accounts payable	_		271		_		
Deferred income taxes	168		177		222		
Liabilities for retirement and severance benefits	263		_		281		
Other non-current liabilities	38		37		37		
Total non-current liabilities	607	0.9	527	0.7	653	0.9	
Total liabilities	25,062	34.7	22,300	30.4	27,029	35.6	
NET ASSETS							
Stockholders' equity:							
Common stock	7,544	10.4	7,544	10.3	7,544	9.9	
Additional paid-in capital	10,485	14.5	· · · · · · · · · · · · · · · · · · ·	14.3	,	13.8	
Retained earnings	28,364	39.3		45.0		40.5	
Treasury stock	-1,017	-1.4		-2.4	-1,755	-2.3	
	45,376	62.8		67.2		61.9	
Total stockholders' equity Valuation and translation adjustments:	43,370	02.0	49,239	07.2	40,703	01.9	
Net unrealized gain on other securities	1,563	2.2	1,267	1.7	1,468	1.9	
-	1,303	0.0	1,207	0.0	1,408	0.0	
Deferred gains on hedges	-58	-0.1	116	0.0	49	0.0	
Foreign currency translation adjustments					-		
Total valuation and translation adjustments	1,515	2.1 0.4	1,384	1.9 0.5	1,519	2.0 0.5	
Minority interests	319		365		361		
Total Net Assets	47,211	65.3	51,010	69.6	48,864	64.4	
Total Liabilities and Net Assets	72,274	100.0	73,310	100.0	75,894	100.0	



(2) Consolidated Statements of Income (Summary)

Consolidated Statements of Income (Summary)						
	First half FY20	First half FY2006 First half FY2007		FY2006		
	Amount	%	Amount	%	Amount	%
Net sales	47,113	100.0	50,730	100.0	96,679	100.0
Cost of sales	24,406	51.8	24,880	49.0	49,246	50.9
Gross profit	22,706	48.2	25,850	51.0	47,432	49.1
Selling, general and administrative expenses	19,409	41.2	20,986	41.4	39,458	40.9
Operating profit	3,296	7.0	4,863	9.6	7,973	8.2
Non-operating profit	353	0.7	266	0.5	815	0.8
Non-operating expenses	92	0.2	212	0.4	341	0.4
Ordinary profit	3,558	7.5	4,918	9.7	8,448	8.7
Extraordinary profit	13	0.0	63	0.1	33	0.1
Extraordinary expenses	159	0.3	_	0.0	171	0.2
Income before income taxes and minority interests	3,411	7.2	4,981	9.8	8,310	8.6
Income taxes	1,332	2.8	2,021	4.0	3,202	3.3
Minority interests	29	0.1	21	0.0	55	0.1
Net income	2,049	4.3	2,938	5.8	5,052	5.2



(3) Consolidated Statements of Cash Flows

	First half FY2006	First half FY2007	FY2006 (Summary)
	Amount		Amount
	Amount	Amount	Amount
Cash flows from operating activities:			
Income before income taxes and minority interests	3,411	4,981	8,310
Depreciation and amortization	742	944	1,698
Amortization of goodwill	74	_	74
Loss on disposal of property, plant and equipment	15	10	99
Allowance for doubtful receivables	18	- 27	- 7
Increase (decrease) in accrued bonuses	396	- 269	739
Increase (decrease) in accrued bonuses to directors and corporate auditors Increase in prepaid pension expenses	- 217	- 77 - 264	77 - 567
Increase (decrease) in directors retirement allowances	- 217	- 204 - 281	26
Interest and dividend income	- 36	- 59	- 82
Interest expenses	29	39	92
Exchange (gain) loss	- 19	- 24	71
Loss on devaluation of investments in securities	_	_	18
Gain on sale of investments in securities	_	_	- 19
Decrease in trade notes and accounts receivable	3,764	2,891	1,599
(Increase) decrease in inventories	- 746	1,687	- 926
Decrease in trade notes and accounts payable	- 1,429	- 2,802	- 1,228
Increase (decrease) in consumption taxes payable	- 80	120	- 124
Equity in earnings of affiliates	- 18	4	- 46
Other, net	- 935	0	- 239
Sub total	4,980	6,874	9,565
Interest and dividend received	36	59	84
Interest paid	- 29	- 40	- 87
Income taxes paid	- 2,293	- 1,871	- 3,680
Net cash provided by operating activities	2,693	5,021	5,882
Cash flows from investing activities:			
Proceeds from sale of investments in securities	_	_	60
Purchase of investments in securities	- 127	- 48	- 461
	- 127	7	
Proceeds from sale of property, plant and equipment	8	/	9
Capital expenditures	- 1,076	- 889	- 2,242
Purchase of intangible assets	- 163	- 188	- 484
Proceeds from purchases of subsidiary stock due to changing scope of consolidation	30	_	30
Other, net	27	45	36
Net cash used in investing activities	- 1,301	- 1,073	- 3,050
Cash flows from financing activities:			
Decrease in short-term debt	- 208	- 795	- 538
Payments on long-term debt	- 16	- 70	- 42
Dividends paid to stockholders	- 575	- 660	- 1,238
Purchase of treasury stock	- 3	- 2	- 740
Other, net	- 28	- 38	- 740 - 31
Net cash used in financing activities	- 831	- 1,567	- 2,591
=	38	- 1,507 - 4	- 2,391 - 17
Effect of exchange rate changes on cash and cash equivalents			
Net increase in cash and cash equivalents	599	2,375	223
Cash and cash equivalents at beginning of year	10,804	11,027	10,804
Cash and cash equivalents at end of year	11,404	13,403	11,027



9. Overseas Sales

First half FY2006 (Millions of yen)

	Americas	Europe	Asia	Other	Total
Overseas sales	3,596	2,992	2,904	393	9,886
Consolidated sales					47,113
Percentage of overseas sales to consolidated sales(%)	7.6	6.4	6.2	0.8	21.0

First half FY2007 (Millions of yen)

	Americas	Europe	Asia	Other	Total
Overseas sales	6,955	3,668	2,861	479	13,964
Consolidated sales					50,730
Percentage of overseas sales to consolidated sales (%)	13.7	7.2	5.6	0.9	27.5

FY2006 (Millions of yen)

	Americas	Europe	Asia	Other	Total
Overseas sales	8,941	6,898	5,317	771	21,928
Consolidated sales					96,679
Percentage of overseas sales to consolidated sales(%)	9.2	7.1	5.5	0.8	22.7

Note: 1. Overseas sales comprise sales of the Company and its consolidated subsidiaries in countries and regions other than Japan.

2. The major countries or regions in the respective divisions are as follows:

Americas: U.S.A., Venezuela and Colombia
Europe: Germany, Italy, Spain, France and Russia
Asia: China, Korea, Thailand and Vietnam